

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-38. (canceled)

39. (currently amended) An isolated polypeptide originating from a malaria erythrocyte membrane protein of the sequence according to amino acids 1-415 of SEQ ID NO:1 ~~consisting of an amino-terminal part of said sequence, and wherein said amino-terminal part of said sequence and~~ comprises domain [[DBL-1]] Duffy-binding-like domain-1 (DBL-1) and said polypeptide binds to a negatively charged ~~heparin sulfate or~~ heparan sulfate and heparan sulfate-like molecule.

40-41. (canceled)

42. (previously presented) A recombinant fusion protein comprising a polypeptide according to claim 39.

43. (previously presented) A pharmaceutical composition, comprising the polypeptide according to claim 39 and a pharmaceutically acceptable carrier.

44. (currently amended) A ~~medicament~~ composition comprising an isolated polypeptide originating from a malaria erythrocyte membrane protein of the sequence according to amino acids 79-415 of SEQ ID NO: 1, wherein said malaria erythrocyte membrane protein ~~of the sequence according to SEQ ID NO:1~~

~~consists of an amino-terminal part of said sequence, and wherein~~
~~said amino-terminal part of the sequence comprises~~ comprising
domain ~~[[DB:-1]]~~ Duffy-binding-like domain-1 (DBL-1), ~~said~~
~~polypeptide binds malaria-infected erythrocytes membrane protein,~~
and wherein said polypeptide binds to a negatively charged
~~heparin sulfate or~~ heparan sulfate and heparan sulfate-like
molecule.

45. (currently amended) The ~~medicament~~ composition
according to claim 44, ~~wherein said medicament is in the form of~~
~~a vaccine~~ further comprising a pharmaceutically acceptable
carrier.

46. (currently amended) An isolated polypeptide
originating from a malaria erythrocyte membrane protein of the
sequence according to amino acids 79-415 of SEQ ID NO: 1
~~consisting of an amino-terminal part of said SEQ ID NO:1, said~~
~~amino-terminal part of said sequence comprises~~ comprising domain
~~[[DBL-1]]~~ Duffy-binding-like domain-1 (DBL-1), ~~said polypeptide~~
~~binds malaria-infected erythrocytes membrane protein,~~ and wherein
said polypeptide binds to a negatively charged ~~heparin sulfate or~~
heparan sulfate and heparan sulfate-like molecule.

47. (canceled)

48. (currently amended) A composition, comprising ~~an~~
~~adjuvant~~ a pharmaceutically acceptable carrier and the
polypeptide according to claim 39.

49-51. (canceled)

52. (new) A recombinant fusion protein comprising a polypeptide according to claim 46.

53. (new) A polypeptide comprising SEQ ID NO: 1.

54. (new) A polypeptide consisting of SEQ ID NO: 1.

55. (new) A polypeptide comprising amino acids 79-415 of SEQ ID NO: 1.

56. (new) A polypeptide consisting of amino acids 79-415 of SEQ ID NO: 1.